Scribe Therapeutics Inc. (SCTX)

NASDAQ: SCTX · Real-Time Price · USD

20.72

-0.05 (-0.24%)

Oct 15, 2026, 4:00 PM EDT - Market closed

Scribe Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	33.3	51.17	27.41
Revenue Growth	-	86.68%	-
Gross Profit	-17.75	-9.62	-29.67
Operating Income	-30.71	-26.07	-42.83
Net Income	-32.3	-21.81	-47.79
Earnings Per Share	-13.18	-8.98	-19.94
EPS Growth	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	43.01	57.96	105.17
Total Debt	43.27	41.43	41.68
Net Cash (Debt)	-0.26	16.54	63.49
Net Cash Growth	-	-73.96%	-
Net Cash Per Share	-0.11	6.81	26.50

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-37.85	-45.21	-45.24
Capital Expenditures	-0.37	-1.27	-1.35
Free Cash Flow	-38.22	-46.48	-46.58
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	-53.29%	-18.80%	-108.22%
Operating Margin	-92.20%	-50.94%	-156.24%
Pretax Margin	-98.01%	-46.14%	-137.02%
Profit Margin	-97.00%	-42.61%	-174.32%
FCF Margin	-114.77%	-90.83%	-169.93%